Current Neurology and Neuroscience Reports

, Volume 12, Issue 1, pp 17–23 | Cite as

Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran

  • Christian Weimar
  • Stefan H. Hohnloser
  • John W. Eikelboom
  • Hans-Christoph Diener
Stroke (HP Adams Jr, Section Editor)


Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. The RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy [with Dabigatran Etexilate]) study showed that dabigatran given at a dose of 110 mg twice a day (bid) was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin (International Normalized Ratio target 2.0–3.0), and lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg bid was significantly more effective compared with warfarin and showed a similar rate of major hemorrhages. Both dosages resulted in an approximately 60% to 70% relative reduction of intracranial hemorrhage. The dosage of 110 mg bid should be preferably used in patients older than 75 years at a higher bleeding risk. The Hemoclot (Hyphen BioMed, Mason, OH) test to measure dabigatran serum concentration is commercially available, but presence of the drug may also be detected using the activated partial thromboplastin time or thrombin time.


Dabigatran Anticoagulants Atrial fibrillation Stroke Prevention 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50(22):2156–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158(3):229–34.PubMedCrossRefGoogle Scholar
  3. 3.
    Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.PubMedGoogle Scholar
  5. 5.
    Weimar C, Benemann J, Katsarava Z, et al. Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol. 2008;60(3):142–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Nabauer M, Gerth A, Limbourg T, et al. The registry of the German competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–37.PubMedCrossRefGoogle Scholar
  8. 8.
    Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805–10. 10 e1-2.PubMedCrossRefGoogle Scholar
  9. 9.
    •• Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. This is the main publication of the RE-LY trial which showed that dabigatran is more effective or safer compared with warfarin.Google Scholar
  10. 10.
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–6. After publication of the main results, additional outcome events were identified after an FDA-mandated search for silent myocardial infarctions.Google Scholar
  11. 11.
    • Wallentin L, Yusuf S, Ezekowitz MD, et al.: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83. The benefits of 150 mg of dabigatran at reducing stroke, 110 mg of dabigatran at reducing bleeding, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centers' quality of INR control. For all vascular events, nonhemorrhagic events, and mortality, advantages of dabigatran were greater at sites with poor INR control than at those with good INR control.Google Scholar
  12. 12.
    Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122(22):2246–53.PubMedCrossRefGoogle Scholar
  13. 13.
    • Diener HC, Connolly SJ, Ezekowitz MD, et al.: Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–63. Most effects of both dabigatran doses were consistent in patients with versus those without previous stroke or TIA.Google Scholar
  14. 14.
    Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Adjusted-dose warfarin versus low-intensity. fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633–8.CrossRefGoogle Scholar
  16. 16.
    Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159(12):1322–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Lechat P, Lardoux H, Mallet A, et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis. 2001;12(3):245–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38(3):874–80.PubMedCrossRefGoogle Scholar
  19. 19.
    • Eikelboom JW, Wallentin L, Connolly SJ, et al.: Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation. 2011;123(21):2363–72. Both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients ages less than 75 years. In those ages ≥75 years, intracranial bleeding risk is lower but extracranial bleeding risk is similar or higher with both doses of dabigatran compared with warfarin. Therefore, the lower dose might be considered a means to reduce the risk of bleeding.Google Scholar
  20. 20.
    Holmes Jr DR, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54(2):95–109.PubMedCrossRefGoogle Scholar
  21. 21.
    Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103(1):13–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Beasley BN, Unger EF, Temple R. Anticoagulant options–why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.PubMedCrossRefGoogle Scholar
  28. 28.
    • van Ryn J, Stangier J, Haertter S, et al.: Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27. This discusses pharmacology data on coagulation assays and reversal of anticoagulant activity under dabigatran.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Christian Weimar
    • 1
  • Stefan H. Hohnloser
    • 2
  • John W. Eikelboom
    • 3
  • Hans-Christoph Diener
    • 1
  1. 1.Department of Neurology and Stroke UnitUniversity of Duisburg- EssenEssenGermany
  2. 2.Division of Clinical Electrophysiology, Department of CardiologyJ. W. Goethe UniversityFrankfurtGermany
  3. 3.Department of MedicineMcMaster University, Population Health Research InstituteHamiltonCanada

Personalised recommendations